LOWELL, Mass., May 15, 2018 /PRNewswire/ -- Alcyone Lifesciences, Inc., a leader in disease modifying therapies for the central nervous system (CNS) through its Advanced Precision Delivery Platforms, announced a presentation on its intrathecal delivery technology platform that has the potential to impact several CNS gene therapies and their development. A poster presentation will be made by Jonathan Freund, R&D Engineer at Alcyone Lifesciences, in collaboration with Professor Bryn Martin, PhD of the University of Idaho.
Delivering disease modifying therapies, such as gene therapy, through the intrathecal space, is a complex, multifactorial and promising modality. Utilizing advanced biomedically engineered, platform solutions that utilize the cerebrospinal fluid (CSF) dynamics to concentrate therapeutics to the targets of interest (TOIs) and increase residence time, can have significant positive impacts with both safety and efficacy for gene therapies.
"The utility of CSF dynamics in controlled precision delivery of gene therapy is one of our primary focuses. We look forward to contributing to the field of CNS gene therapy," said Deep Singh, vice president of research and development at Alcyone Lifesciences.
"It is a pleasure to apply my lab's expertise in cerebrospinal fluid dynamics to help innovate CNS drug delivery systems in partnership with Alcyone Lifesciences," said Bryn Martin, Ph.D., assistant professor of biological engineering at University of Idaho.
Poster Presentation Information:Session Date/Time: Thursday May 17, 2018, 5:15 PM - 7:15 PMSession Title: Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics IRoom: Stevens Salon C, DFinal Abstract Number: 620Title: Intrathecal Drug Delivery Platform for Gene Therapy: An In Vitro & In Vivo Delivery Study
About Alcyone Lifesciences, Inc.Alcyone Lifesciences, based in Lowell, Massachusetts, is a privately-held therapeutic device company and a leader in transforming disease modifying therapies for rare and orphan disorders through its Advanced Precision Delivery Platforms. For more information, please visit http://www.alcyonels.com/
ContactAlcyone Lifesciences, Inc.PJ AnandChief Executive [email protected]
Advertisement
Delivering disease modifying therapies, such as gene therapy, through the intrathecal space, is a complex, multifactorial and promising modality. Utilizing advanced biomedically engineered, platform solutions that utilize the cerebrospinal fluid (CSF) dynamics to concentrate therapeutics to the targets of interest (TOIs) and increase residence time, can have significant positive impacts with both safety and efficacy for gene therapies.
Advertisement
"The utility of CSF dynamics in controlled precision delivery of gene therapy is one of our primary focuses. We look forward to contributing to the field of CNS gene therapy," said Deep Singh, vice president of research and development at Alcyone Lifesciences.
"It is a pleasure to apply my lab's expertise in cerebrospinal fluid dynamics to help innovate CNS drug delivery systems in partnership with Alcyone Lifesciences," said Bryn Martin, Ph.D., assistant professor of biological engineering at University of Idaho.
Poster Presentation Information:Session Date/Time: Thursday May 17, 2018, 5:15 PM - 7:15 PMSession Title: Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics IRoom: Stevens Salon C, DFinal Abstract Number: 620Title: Intrathecal Drug Delivery Platform for Gene Therapy: An In Vitro & In Vivo Delivery Study
About Alcyone Lifesciences, Inc.Alcyone Lifesciences, based in Lowell, Massachusetts, is a privately-held therapeutic device company and a leader in transforming disease modifying therapies for rare and orphan disorders through its Advanced Precision Delivery Platforms. For more information, please visit http://www.alcyonels.com/
ContactAlcyone Lifesciences, Inc.PJ AnandChief Executive [email protected]
View original content:http://www.prnewswire.com/news-releases/alcyone-lifesciences-announces-presentation-on-intrathecal-physical-methods-of-delivery-of-gene-therapeutics-at-2018-american-society-of-cell-and-gene-therapy-conference-300648284.html
SOURCE Alcyone Lifesciences, Inc.
